Please type a plus sign (+) inside this box

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR

Attorney Docket No.		LEX-0182-USA	
First Inventor		Turner, Jr., et al.	
Title	Novel Human Mitochondrial Proteins and Polynucleotides Enco		
		T	

1.53 (b))		Express Mail Label No.	EL 826373505 US		
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application		ADDRESS TO:	Assistant Commissioner for Patents Box Patent Application Washington, DC 20231		
2 X Applicant clair See 37 CFR Specification (preferred arrange) - Descriptive title - Cross Referen	[Total Pages 63] ement set forth below) e of the Invention ce to Related Applications	Nucleotide and/or Ar (if applicable, all ned X Comp	outer Readable Form (CRF)		
- Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the drawings (if filed) - Detailed Description - Claim(s) - Abstract of the disclosure			paper		
		10. 37 CFR 3.7 (when there	Papers (cover sheet & document(s)) 3(b) Statement		
5. Oath or Declaration a. X Unexecut	[TotalPages 2] ed (original or copy)	12. Information Statement (Disclosure Copies of IDS IDS)/PTO-1449 Citations		
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).		15. Certified Co	eipt Postcard (MPEP 503) specifically itemized) ppy of Priority Document(s) riority is claimed) tion Request under 35 U.S.C. 122 Applicant must attach form PTO/SB/35 alent		
Application Data Sheet. See 37 CFR 1.76					
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No.: / Prior application information: Examiner Group Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.					
19. CORRESPONDENCE ADDRESS					
Customer Number o	or Bar Code Label (Insert Customer No	o. gr Attach bar code label here)	or Correspondence address below		
Name PATENT TRADEMARK OFFICE					
Address					
City	State		Zip		
Country	Telephon		Fax		
Name (Print/Type) Lance K Shimotø Registration No. (Attorney/Agent) 41866 Signature Date 5-30/0 /					
_ —————————————————————————————————————		4	المتعادي والمتعادي		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

NONPUBLICATION REQUEST UNDER 35 U.S.C. 122(b)(2)(B)(i)

First Named Inventor Turner, Jr., et al.

Title Novel Human Mitochondrial Proteins and Polynucleotides Encoding the Same

Atty Docket Number LEX-0182-USA

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

I hereby request that the attached application not be published under 35 U.S.C. 122(b).

5/30 | 01

Signature

Lance K. Ishimoto
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing.**

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**